Literature DB >> 32240838

Association between liver fibrosis scores and the risk of mortality among patients with coronary artery disease.

Qian Chen1, Qing Li2, Dan Li3, Xuechen Chen2, Zhaomin Liu3, Gang Hu4, Jingfeng Wang5, Wenhua Ling6.   

Abstract

BACKGROUND AND AIMS: Fatty liver diseases are highly prevalent in patients with coronary artery disease (CAD) and might progress to irreversible liver fibrosis. Whether baseline liver fibrosis (LF) scores are associated with long-term mortality among patients with CAD requires investigation.
METHODS: The analysis was conducted based on a prospective cohort study among 3263 patients with CAD in China. Cox models were used to assess the association of baseline levels of LF scores, including non-alcoholic fatty liver disease fibrosis score (NFS), fibrosis 4 score (FIB-4), aspartate aminotransferase to platelet ratio index (APRI), gamma-glutamyltransferase to platelet ratio (GPR), and Forns score, with the risk of all-cause and cardiovascular mortality among CAD patients.
RESULTS: During a median follow-up period of 7.56 (inter-quartile range: 6.86-8.31) years, 538 deaths were identified, 319 of those were due to cardiovascular diseases. Compared with patients with lowest score levels, multivariable-adjusted HRs (95% CI) for those with highest levels of NFS, FIB-4, APRI, GPR and Forns score were 2.89 (2.14-3.91), 2.84 (2.14-3.76), 1.77 (1.33-2.36), 1.47 (1.19-1.83) and 3.10 (1.88-5.11) for all-cause mortality, 3.02 (2.05-4.45), 3.34 (2.29-4.86), 1.99 (1.40-2.83), 1.80 (1.36-2.39) and 2.43 (1.28-4.61) for cardiovascular mortality, respectively. These associations were consistent when we excluded those who died within the first year of follow-up or stratified patients by different sex, age, BMI, diabetes status, metabolic syndrome status, CAD type and hsCRP level.
CONCLUSIONS: Higher LF scores are associated with increased risks of all-cause and cardiovascular mortality among CAD patients. LF scores might play a potential role in CAD prognosis prediction.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  All-cause mortality; Cardiovascular mortality; Cohort study; Coronary artery disease; Liver fibrosis score

Mesh:

Year:  2020        PMID: 32240838     DOI: 10.1016/j.atherosclerosis.2020.03.010

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  13 in total

1.  Relationship between non-invasively detected liver fibrosis and in-hospital outcomes in patients with acute coronary syndrome undergoing PCI.

Authors:  Flavio Giuseppe Biccirè; Francesco Barillà; Emanuele Sammartini; Edoardo Maria Dacierno; Gaetano Tanzilli; Daniele Pastori
Journal:  Clin Res Cardiol       Date:  2022-08-11       Impact factor: 6.138

2.  Prevalence and Risk Factors of Cardiovascular Disease in Patients with Chronic Hepatitis B.

Authors:  Ho Soo Chun; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim
Journal:  Dig Dis Sci       Date:  2021-09-02       Impact factor: 3.487

3.  High fibrosis-4 index predicts the new onset of ischaemic heart disease during a 10-year period in a general population.

Authors:  Yukimura Higashiura; Marenao Tanaka; Kazuma Mori; Takuma Mikami; Itaru Hosaka; Hirofumi Ohnishi; Nagisa Hanawa; Masato Furuhashi
Journal:  Eur Heart J Open       Date:  2022-04-16

4.  Liver Fibrosis Scoring Systems as Novel Tools for Predicting Cardiovascular Outcomes in Patients Following Elective Percutaneous Coronary Intervention.

Authors:  Hui-Hui Liu; Ye-Xuan Cao; Jing-Lu Jin; Qi Hua; Yan-Fang Li; Yuan-Lin Guo; Cheng-Gang Zhu; Na-Qiong Wu; Run-Lin Gao; Jian-Jun Li
Journal:  J Am Heart Assoc       Date:  2021-01-28       Impact factor: 5.501

5.  Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease.

Authors:  Stefano Ballestri; Alessandro Mantovani; Enrica Baldelli; Simonetta Lugari; Mauro Maurantonio; Fabio Nascimbeni; Alessandra Marrazzo; Dante Romagnoli; Giovanni Targher; Amedeo Lonardo
Journal:  Diagnostics (Basel)       Date:  2021-01-09

6.  Association of the Non-Alcoholic Fatty Liver Disease Fibrosis Score with subclinical myocardial remodeling in patients with type 2 diabetes: A cross-sectional study in China.

Authors:  Nengguang Fan; Xiaoying Ding; Qin Zhen; Liping Gu; Aifang Zhang; Tingting Shen; Yufan Wang; Yongde Peng
Journal:  J Diabetes Investig       Date:  2021-01-08       Impact factor: 4.232

7.  NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study.

Authors:  Jia Peng; Ming-Ming Liu; Jing-Lu Jin; Ye-Xuan Cao; Yuan-Lin Guo; Na-Qiong Wu; Cheng-Gang Zhu; Qian Dong; Jing Sun; Rui-Xia Xu; Jian-Jun Li
Journal:  Lipids Health Dis       Date:  2022-01-07       Impact factor: 3.876

8.  Gamma-Glutamyl Transpeptidase to Platelet Ratio: A New Inflammatory Marker Associated with Outcomes after Cardiac Arrest.

Authors:  Yipin Zhao; Zebin Lin; Yingying Ji; Huawei Wang; Li Xiao; Qingwei Chen; Zhiqin Wu
Journal:  Mediators Inflamm       Date:  2021-08-13       Impact factor: 4.711

9.  AST to Platelet Ratio Index (APRI) is an easy-to-use predictor score for cardiovascular risk in metabolic subjects.

Authors:  Carlo De Matteis; Marica Cariello; Giusi Graziano; Stefano Battaglia; Patrizia Suppressa; Giuseppina Piazzolla; Carlo Sabbà; Antonio Moschetta
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

10.  The association of hepatic steatosis and fibrosis with heart failure and mortality.

Authors:  Jiyun Park; Gyuri Kim; Hasung Kim; Jungkuk Lee; You-Bin Lee; Sang-Man Jin; Kyu Yeon Hur; Jae Hyeon Kim
Journal:  Cardiovasc Diabetol       Date:  2021-09-28       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.